Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

Next Previous
Trial Profile

Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STC-15 (Primary) ; Toripalimab
  • Indications Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Storm Therapeutics

Most Recent Events

  • 27 May 2025 According to Storm Therapeutics media release, company announced a clinical collaboration with STORM Therapeutics, to evaluate STC-15 in combination with toripalimab in a Phase 1b/2 study for the treatment of non-small cell lung cancer, head and neck squamous cell carcinoma , melanoma and endometrial cancer.
  • 27 May 2025 According to Storm Therapeutics media release, the company announced dosing of its first patient in a collaboration with Coherus BioSciences, Inc
  • 23 May 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top